Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.45 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | PIP5K1C | O60331 | 10/20 | 0.41 |
| ▸ | DHODH | Q02127 | 1/20 | 0.40 |
| ▸ | FOXO1 | Q12778 | 1/20 | 0.39 |
| ▸ | WNT1 | P04628 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4106602 | 0.93 | CHEK1 (0.45) | CHEK1PDPK1KDRFLT3PIP5K1C | |
| SCHEMBL4104292 | 0.87 | CHEK1 (0.47) | CHEK1PDPK1FLT3PIP5K1CDHODH | |
| SCHEMBL4090783 | 0.86 | CHEK1 (0.56) | CHEK1PDPK1FLT3PIP5K1CFOXO1 | |
| SCHEMBL13849203 | 0.83 | PAK4 (0.48) | CHEK1PDPK1FLT3PIP5K1CDHODH | |
| SCHEMBL19198782 | 0.81 | FLT3 (0.44) | CHEK1PDPK1KDRFLT3PIP5K1C | |
| SCHEMBL13849215 | 0.81 | FLT3 (0.48) | CHEK1PDPK1FLT3DHODH | |
| SCHEMBL13849193 | 0.81 | FLT3 (0.52) | CHEK1PDPK1FLT3DHODH | |
| SCHEMBL13849204 | 0.81 | FLT3 (0.44) | CHEK1PDPK1FLT3PIP5K1CDHODH | |
| SCHEMBL13849211 | 0.79 | FLT3 (0.41) | CHEK1PDPK1FLT3PIP5K1CDHODH | |
| SCHEMBL13849212 | 0.79 | FLT3 (0.48) | CHEK1PDPK1FLT3DHODHDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131470-A1 | PYRAZOLE-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER AND AUTOIMMUNE DISORDERS | VERNALIS R & D LIMITED (GB) | 2009-05-21 | — | — | US | disclosed |
| US-20090131470-A1 | PYRAZOLE-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER AND AUTOIMMUNE DISORDERS | VERNALIS R & D LIMITED (GB) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131470-A1 | PYRAZOLE-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER AND AUTOIMMUNE DISORDERS | PDK1, CHEK1, PDK3 | CHEK1 2/4885PDPK1 16/4885KDR 1037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.